Prominent rash and multisystem inflammatory syndrome in a 29-year-old patient with COVID-19: a case report

Background Adult patients with coronavirus disease present primarily with respiratory symptoms, but children and some adults may display a more systemic inflammatory syndrome with rash, fever, mucosal changes, and elevated inflammatory biomarkers. Case presentation Here, we report the case of a 29-year-old Hispanic patient presenting with significant rash and multisystem inflammation. We describe his clinical course, review dermatological manifestations of coronavirus disease, and summarize the pathophysiology of coronavirus disease-associated multisystem inflammation. Conclusion This case should alert physicians to the atypical nature of presenting rash with minimal respiratory symptoms in coronavirus disease.

Successful therapeutic response with sequential therapy of rituximab and belimumab in a hispanic patient with refractory lupus nephritis

Lupus nephritis (LN) is the most common severe organ manifestation of systemic lupus erythematosus (SLE). Life expectancy and renal survival is reduced in these patients. A partial remission in LN is associated with a significantly better patient and renal survival rate compared with no remission. We report the case of a 27-year-old Hispanic patient with diffuse proliferative lupus nephritis (grade IV with high activity index) managed with induction therapy with mycophenolate mophethyl (MMF, 1000 mg daily escalating to 3000 mg daily and prednisone (PDN) 1 mg/kg/day. Progression of proteinuria with preserved renal function and extra-renal activity were observed (alopecia). Re-induction with IV cyclophosphamide (CYC, 1 gr.) and pulse IV methylprednisolone (500 mg for three days) was administered, followed by a lower starting dose of PDN (0.5 mg/kg/day). Treatment failure was observed. A second renal biopsy evidenced renal damage (chronicity index 4/12 and activity index 4/24). The patient also developed non-renal clinical manifestations (malar rash, oral ulcers and arthritis). Treatment with IV rituximab (RTX) 1000 mg X2 associated with MMF 1000 mg per day and IV methylprednisolone 500 mg X3 was initiated, followed by PDN 0.5 mg/kg/day with a dose-tapering scheme similar to CYC re-induction. Treatment continued with IV Belimumab (BLM) 600 mg every month associated with MMF 1000 mg per day. Sequential therapy with RTX + BLM showed a partial renal and complete extra-renal response in a patient with severe lupus despite two 2 immunosuppressive treatment schemes.

Lipofibromatous Hamartoma in a Hispanic Patient with macrodactyly: a rare peripheral nerve tumor causing recurrent carpal tunnel syndrome

This is a rare case of a 42-year-old Hispanic male with macrodactyly who presented with recurrent carpal tunnel syndrome (CTS) due to Lipofibromatous Hamartoma (LFH). A slowly growing mass in his right palm with pain and numbness, along with motor and sensory deficits in the median nerve distribution, was reported since the past year prior to visit. Previous open carpal tunnel release was performed at 16 years of age due to CTS without complications. The diagnosis of LFH was made based on ultrasound, electromyography test and physical examination. An extended open carpal tunnel release with transection of transverse ligament was performed. The 24-month postoperative evaluation showed complete resolution of symptoms. This report illustrates the management of a recurrent CTS due to LFH in a Hispanic adult patient with macrodactyly that was successfully treated with a carpal tunnel decompression.

Personalized approach for patients with heart failure and diabetes: responding to current unmet needs

67-year-old female hispanic patient presented with effort angina, dyspnea, and fatigue despite pharmacologic therapy.